Dr. Benjamin Izar’s work leverages natural and synthetic protein variants to enhance T cell function in cancer immunotherapy. His team’s cutting-edge methods generate thousands of variants to improve CAR T and TIL therapies, showing promising results in pre-clinical mouse models of melanoma and leukemia. Dr. Izar aims to address resistance mechanisms and enhance the efficacy of cellular therapies for solid and hematologic cancers.
Projects and Grants
Enhancing Cellular Cancer Immunotherapies through Massively Parallel Discovery of Novel Protein Variants Coupled with Functional Single-Cell Multi-Omics
Columbia University | All Cancers | 2024
